Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers

L. Záveský, E. Jandáková, V. Weinberger, L. Minář, V. Hanzíková, D. Dušková, A. Faridová, R. Turyna, O. Slanař, A. Hořínek, M. Kohoutová

. 2022 ; 49 (3) : 1955-1971. [pub] 20220107

Language English Country Netherlands

Document type Journal Article

Grant support
Progres Q28/LF1 Charles University, Prague
Progres Q25/LF1 Charles University, Prague
RVO-VFN 64165 Ministry of Health of the Czech Republic
CZ-DRO FNBr 65269705 Ministry of Health of the Czech Republic
SSD2018\100022 Avast Foundation
1410002385 ČEPS, a.s.
1410002088 ČEPS, a.s.
1410002640 ČEPS, a.s.

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago

BACKGROUND: Breast cancer is a leading cause of cancer-related death in women. Most cases are invasive ductal carcinomas of no special type (NST breast carcinomas). METHODS AND RESULTS: In this prospective, multicentric biomarker discovery study, we analyzed the expression of small non-coding RNAs (mainly microRNAs) in plasma by qPCR and evaluated their association with NST breast cancer. Large-scale expression profiling and subsequent validations have been performed in patient and control groups and compared with clinicopathological data. Small nuclear U6 snRNA, miR-548b-5p and miR-451a have been identified as candidate biomarkers. U6 snRNA was remarkably overexpressed in all the validations, miR-548b-5p levels were generally elevated and miR-451a expression was mostly downregulated in breast cancer groups. Combined U6 snRNA/miR-548b-5p signature demonstrated the best diagnostic performance based on the ROC curve analysis with AUC of 0.813, sensitivity 73.1% and specificity 82.6%. There was a trend towards increased expression of both miR-548b-5p and U6 snRNA in more advanced stages. Further, increased miR-548b-5p levels have been partially associated with higher grades, multifocality, Ki-67 positivity, and luminal B rather than luminal A samples. On the other hand, an association has been observed between high miR-451a expression and progesterone receptor positivity, lower grade, unifocal samples, Ki-67-negativity, luminal A rather than luminal B samples as well as improved progression-free survival and overall survival. CONCLUSIONS: Our results indicated that U6 snRNA and miR-548b-5p may have pro-oncogenic functions, while miR-451a may act as tumor suppressor in breast cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019313
003      
CZ-PrNML
005      
20220804135543.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11033-021-07010-8 $2 doi
035    __
$a (PubMed)34993725
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Záveský, Luděk $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic. ludek.zavesky@gmail.com $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic. ludek.zavesky@gmail.com $1 https://orcid.org/0000000195927535 $7 jo2013742232
245    10
$a Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers / $c L. Záveský, E. Jandáková, V. Weinberger, L. Minář, V. Hanzíková, D. Dušková, A. Faridová, R. Turyna, O. Slanař, A. Hořínek, M. Kohoutová
520    9_
$a BACKGROUND: Breast cancer is a leading cause of cancer-related death in women. Most cases are invasive ductal carcinomas of no special type (NST breast carcinomas). METHODS AND RESULTS: In this prospective, multicentric biomarker discovery study, we analyzed the expression of small non-coding RNAs (mainly microRNAs) in plasma by qPCR and evaluated their association with NST breast cancer. Large-scale expression profiling and subsequent validations have been performed in patient and control groups and compared with clinicopathological data. Small nuclear U6 snRNA, miR-548b-5p and miR-451a have been identified as candidate biomarkers. U6 snRNA was remarkably overexpressed in all the validations, miR-548b-5p levels were generally elevated and miR-451a expression was mostly downregulated in breast cancer groups. Combined U6 snRNA/miR-548b-5p signature demonstrated the best diagnostic performance based on the ROC curve analysis with AUC of 0.813, sensitivity 73.1% and specificity 82.6%. There was a trend towards increased expression of both miR-548b-5p and U6 snRNA in more advanced stages. Further, increased miR-548b-5p levels have been partially associated with higher grades, multifocality, Ki-67 positivity, and luminal B rather than luminal A samples. On the other hand, an association has been observed between high miR-451a expression and progesterone receptor positivity, lower grade, unifocal samples, Ki-67-negativity, luminal A rather than luminal B samples as well as improved progression-free survival and overall survival. CONCLUSIONS: Our results indicated that U6 snRNA and miR-548b-5p may have pro-oncogenic functions, while miR-451a may act as tumor suppressor in breast cancer.
650    _2
$a biologické markery $7 D015415
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a nádory prsu $x diagnóza $x genetika $x patologie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x genetika $7 D015972
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a RNA malá jaderná $7 D012342
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jandáková, Eva $u Department of Pathology, Faculty of Medicine, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00, Brno, Czech Republic
700    1_
$a Weinberger, Vít $u Department of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00, Brno, Czech Republic
700    1_
$a Minář, Luboš $u Department of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00, Brno, Czech Republic
700    1_
$a Hanzíková, Veronika $u Faculty Transfusion Center, General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic
700    1_
$a Dušková, Daniela $u Faculty Transfusion Center, General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic
700    1_
$a Faridová, Adéla $u Institute for Mother and Child Care, Podolské nábřeží 157/36, 147 00, Prague - Podolí, Czech Republic
700    1_
$a Turyna, Radovan $u Institute for Mother and Child Care, Podolské nábřeží 157/36, 147 00, Prague - Podolí, Czech Republic
700    1_
$a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic
700    1_
$a Hořínek, Aleš $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic $u 3rd Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
700    1_
$a Kohoutová, Milada $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic
773    0_
$w MED00003392 $t Molecular biology reports $x 1573-4978 $g Roč. 49, č. 3 (2022), s. 1955-1971
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34993725 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135537 $b ABA008
999    __
$a ok $b bmc $g 1822774 $s 1170556
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 49 $c 3 $d 1955-1971 $e 20220107 $i 1573-4978 $m Molecular biology reports $n Mol Biol Rep $x MED00003392
GRA    __
$a Progres Q28/LF1 $p Charles University, Prague
GRA    __
$a Progres Q25/LF1 $p Charles University, Prague
GRA    __
$a RVO-VFN 64165 $p Ministry of Health of the Czech Republic
GRA    __
$a CZ-DRO FNBr 65269705 $p Ministry of Health of the Czech Republic
GRA    __
$a SSD2018\100022 $p Avast Foundation
GRA    __
$a 1410002385 $p ČEPS, a.s.
GRA    __
$a 1410002088 $p ČEPS, a.s.
GRA    __
$a 1410002640 $p ČEPS, a.s.
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...